20-Feb-2026
Cathie Wood's weekly recap: adds AMD, CRSP; cuts PINS, PD, TER
Seeking Alpha News (Mon, 23-Feb 7:46 AM ET)
Cathie Wood Loads Up on Biotech Stocks While Trimming Several Tech Positions
TipRanks (Thu, 19-Feb 9:15 AM ET)
Cathie Wood Loads Up on Biotech Stocks While Trimming Tech Positions
TipRanks (Thu, 19-Feb 12:09 AM ET)
Cathie Wood Loads Up on Biotech Stocks While Trimming Tech Positions, 2/18/26
TipRanks (Thu, 19-Feb 12:09 AM ET)
Globe Newswire (Thu, 12-Feb 4:30 PM ET)
Globe Newswire (Wed, 28-Jan 8:05 AM ET)
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
Globe Newswire (Mon, 12-Jan 8:36 AM ET)
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 5-Jan 8:30 AM ET)
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Globe Newswire (Tue, 16-Dec 12:00 PM ET)
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
PRNewswire (Tue, 9-Dec 11:58 AM ET)
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Crispr Therapeutics Ag - Common Shares trades on the NASDAQ stock market under the symbol CRSP.
As of February 20, 2026, CRSP stock price declined to $53.46 with 1,237,126 million shares trading.
CRSP has a beta of 1.58, meaning it tends to be more sensitive to market movements. CRSP has a correlation of 0.22 to the broad based SPY ETF.
CRSP has a market cap of $5.13 billion. This is considered a Mid Cap stock.
Last quarter Crispr Therapeutics Ag - Common Shares reported $864,000 in Revenue and -$1.37 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.17.
In the last 3 years, CRSP traded as high as $91.10 and as low as $30.04.
The top ETF exchange traded funds that CRSP belongs to (by Net Assets): ARKK, IWM, ARKG, XBI, VXF.
CRSP has underperformed the market in the last year with a return of +6.0%, while SPY returned +14.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CRSP shares. However, CRSP has outperformed the market in the last 3 month and 2 week periods, returning +8.5% and +9.7%, while SPY returned +6.0% and -0.2%, respectively. This indicates CRSP has been having a stronger performance recently.
CRSP support price is $52.23 and resistance is $57.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRSP shares will trade within this expected range on the day.